1
|
López-Soldado I, Torres AG, Ventura R, Martínez-Ruiz I, Díaz-Ramos A, Planet E, Cooper D, Pazderska A, Wanic K, O'Hanlon D, O'Gorman DJ, Carbonell T, de Pouplana LR, Nolan JJ, Zorzano A, Hernández-Alvarez MI. Decreased expression of mitochondrial aminoacyl-tRNA synthetases causes downregulation of OXPHOS subunits in type 2 diabetic muscle. Redox Biol 2023; 61:102630. [PMID: 36796135 PMCID: PMC9958393 DOI: 10.1016/j.redox.2023.102630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Revised: 01/26/2023] [Accepted: 02/06/2023] [Indexed: 02/10/2023] Open
Abstract
Type 2 diabetes mellitus (T2D) affects millions of people worldwide and is one of the leading causes of morbidity and mortality. The skeletal muscle (SKM) is one of the most important tissues involved in maintaining glucose homeostasis and substrate oxidation, and it undergoes insulin resistance in T2D. In this study, we identify the existence of alterations in the expression of mitochondrial aminoacyl-tRNA synthetases (mt-aaRSs) in skeletal muscle from two different forms of T2D: early-onset type 2 diabetes (YT2) (onset of the disease before 30 years of age) and the classical form of the disease (OT2). GSEA analysis from microarray studies revealed the repression of mitochondrial mt-aaRSs independently of age, which was validated by real-time PCR assays. In agreement with this, a reduced expression of several encoding mt-aaRSs was also detected in skeletal muscle from diabetic (db/db) mice but not in obese ob/ob mice. In addition, the expression of the mt-aaRSs proteins most relevant in the synthesis of mitochondrial proteins, threonyl-tRNA, and leucyl-tRNA synthetases (TARS2 and LARS2) were also repressed in muscle from db/db mice. It is likely that these alterations participate in the reduced expression of proteins synthesized in the mitochondria detected in db/db mice. We also document an increased iNOS abundance in mitochondrial-enriched muscle fractions from diabetic mice that may inhibit aminoacylation of TARS2 and LARS2 by nitrosative stress. Our results indicate a reduced expression of mt-aaRSs in skeletal muscle from T2D patients, which may participate in the reduced expression of proteins synthesized in mitochondria. An enhanced mitochondrial iNOS could play a regulatory role in diabetes.
Collapse
Affiliation(s)
- Iliana López-Soldado
- Department de Bioquímica i Biomedicina Molecular, Facultat de Biología, 08028, Spain; Institut de Biomedicina de la Universitat de Barcelona IBUB, Barcelona, Spain
| | - Adrian Gabriel Torres
- Institute for Research in Biomedicine (IRB Barcelona), the Barcelona Institute of Science and Technology, Barcelona, Spain
| | - Raúl Ventura
- Department de Bioquímica i Biomedicina Molecular, Facultat de Biología, 08028, Spain; Institut de Biomedicina de la Universitat de Barcelona IBUB, Barcelona, Spain
| | - Inma Martínez-Ruiz
- Department de Bioquímica i Biomedicina Molecular, Facultat de Biología, 08028, Spain; Institut de Biomedicina de la Universitat de Barcelona IBUB, Barcelona, Spain
| | - Angels Díaz-Ramos
- Institute for Research in Biomedicine (IRB Barcelona), the Barcelona Institute of Science and Technology, Barcelona, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Spain
| | - Evarist Planet
- Institute for Research in Biomedicine (IRB Barcelona), the Barcelona Institute of Science and Technology, Barcelona, Spain
| | - Diane Cooper
- National Institute for Cellular Biotechnology, 3U Diabetes Partnership & School of Health and Human Performance, Dublin City University, Dublin, Ireland
| | - Agnieszka Pazderska
- Metabolic Research Unit, St James's Hospital, and Trinity College, Dublin, Ireland
| | - Krzysztof Wanic
- Metabolic Research Unit, St James's Hospital, and Trinity College, Dublin, Ireland
| | - Declan O'Hanlon
- Metabolic Research Unit, St James's Hospital, and Trinity College, Dublin, Ireland
| | - Donal J O'Gorman
- National Institute for Cellular Biotechnology, 3U Diabetes Partnership & School of Health and Human Performance, Dublin City University, Dublin, Ireland
| | - Teresa Carbonell
- Departament de Biologia Cel·lular, Fisiologia i Immunologia, Facultat de Biologia, 08028, Barcelona, Spain
| | - Lluís Ribas de Pouplana
- Institute for Research in Biomedicine (IRB Barcelona), the Barcelona Institute of Science and Technology, Barcelona, Spain
| | - John J Nolan
- Metabolic Research Unit, St James's Hospital, and Trinity College, Dublin, Ireland
| | - Antonio Zorzano
- Department de Bioquímica i Biomedicina Molecular, Facultat de Biología, 08028, Spain; Institute for Research in Biomedicine (IRB Barcelona), the Barcelona Institute of Science and Technology, Barcelona, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Spain.
| | - María Isabel Hernández-Alvarez
- Department de Bioquímica i Biomedicina Molecular, Facultat de Biología, 08028, Spain; Institut de Biomedicina de la Universitat de Barcelona IBUB, Barcelona, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Spain.
| |
Collapse
|
2
|
Ejarque M, Ceperuelo-Mallafré V, Serena C, Maymo-Masip E, Duran X, Díaz-Ramos A, Millan-Scheiding M, Núñez-Álvarez Y, Núñez-Roa C, Gama P, Garcia-Roves PM, Peinado MA, Gimble JM, Zorzano A, Vendrell J, Fernández-Veledo S. Adipose tissue mitochondrial dysfunction in human obesity is linked to a specific DNA methylation signature in adipose-derived stem cells. Int J Obes (Lond) 2018; 43:1256-1268. [PMID: 30262812 PMCID: PMC6760577 DOI: 10.1038/s41366-018-0219-6] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2018] [Revised: 08/23/2018] [Accepted: 09/02/2018] [Indexed: 02/07/2023]
Abstract
Background A functional population of adipocyte precursors, termed adipose-derived stromal/stem cells (ASCs), is crucial for proper adipose tissue (AT) expansion, lipid handling, and prevention of lipotoxicity in response to chronic positive energy balance. We previously showed that obese human subjects contain a dysfunctional pool of ASCs. Elucidation of the mechanisms underlying abnormal ASC function might lead to therapeutic interventions for prevention of lipotoxicity by improving the adipogenic capacity of ASCs. Methods Using epigenome-wide association studies, we explored the impact of obesity on the methylation signature of human ASCs and their differentiated counterparts. Mitochondrial phenotyping of lean and obese ASCs was performed. TBX15 loss- and gain-of-function experiments were carried out and western blotting and electron microscopy studies of mitochondria were performed in white AT biopsies from lean and obese individuals. Results We found that DNA methylation in adipocyte precursors is significantly modified by the obese environment, and adipogenesis, inflammation, and immunosuppression were the most affected pathways. Also, we identified TBX15 as one of the most differentially hypomethylated genes in obese ASCs, and genetic experiments revealed that TBX15 is a regulator of mitochondrial mass in obese adipocytes. Accordingly, morphological analysis of AT from obese subjects showed an alteration of the mitochondrial network, with changes in mitochondrial shape and number. Conclusions We identified a DNA methylation signature in adipocyte precursors associated with obesity, which has a significant impact on the metabolic phenotype of mature adipocytes.
Collapse
Affiliation(s)
- Miriam Ejarque
- Hospital Universitari de Tarragona Joan XXIII-Institut d´Investigació Sanitària Pere Virgili-Universitat Rovira i Virgili, Tarragona, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain
| | - Victoria Ceperuelo-Mallafré
- Hospital Universitari de Tarragona Joan XXIII-Institut d´Investigació Sanitària Pere Virgili-Universitat Rovira i Virgili, Tarragona, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain
| | - Carolina Serena
- Hospital Universitari de Tarragona Joan XXIII-Institut d´Investigació Sanitària Pere Virgili-Universitat Rovira i Virgili, Tarragona, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain
| | - Elsa Maymo-Masip
- Hospital Universitari de Tarragona Joan XXIII-Institut d´Investigació Sanitària Pere Virgili-Universitat Rovira i Virgili, Tarragona, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain
| | - Xevi Duran
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain
| | - Angels Díaz-Ramos
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain.,Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.,Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain
| | - Monica Millan-Scheiding
- Hospital Universitari de Tarragona Joan XXIII-Institut d´Investigació Sanitària Pere Virgili-Universitat Rovira i Virgili, Tarragona, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain
| | - Yaiza Núñez-Álvarez
- Health Sciences Research Institute Germans Trias i Pujol (IGTP)-Institute of Predictive and Personalized Medicine of Cancer (IMPPC), Badalona, Spain
| | - Catalina Núñez-Roa
- Hospital Universitari de Tarragona Joan XXIII-Institut d´Investigació Sanitària Pere Virgili-Universitat Rovira i Virgili, Tarragona, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain
| | - Pau Gama
- Department of Physiological Sciences II, Faculty of Medicine-University of Barcelona, Hospitalet del Llobregat, Barcelona, Spain
| | - Pablo M Garcia-Roves
- Department of Physiological Sciences II, Faculty of Medicine-University of Barcelona, Hospitalet del Llobregat, Barcelona, Spain
| | - Miquel A Peinado
- Health Sciences Research Institute Germans Trias i Pujol (IGTP)-Institute of Predictive and Personalized Medicine of Cancer (IMPPC), Badalona, Spain
| | - Jeffrey M Gimble
- LaCell LLC and Center for Stem Cell Research and Regenerative Medicine, School of Medicine, Tulane University, New Orleans, LA, USA
| | - Antonio Zorzano
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain.,Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.,Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain
| | - Joan Vendrell
- Hospital Universitari de Tarragona Joan XXIII-Institut d´Investigació Sanitària Pere Virgili-Universitat Rovira i Virgili, Tarragona, Spain. .,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain.
| | - Sonia Fernández-Veledo
- Hospital Universitari de Tarragona Joan XXIII-Institut d´Investigació Sanitària Pere Virgili-Universitat Rovira i Virgili, Tarragona, Spain. .,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain.
| |
Collapse
|
3
|
Rodríguez-Nuevo A, Díaz-Ramos A, Noguera E, Díaz-Sáez F, Duran X, Muñoz JP, Romero M, Plana N, Sebastián D, Tezze C, Romanello V, Ribas F, Seco J, Planet E, Doctrow SR, González J, Borràs M, Liesa M, Palacín M, Vendrell J, Villarroya F, Sandri M, Shirihai O, Zorzano A. Mitochondrial DNA and TLR9 drive muscle inflammation upon Opa1 deficiency. EMBO J 2018; 37:embj.201796553. [PMID: 29632021 DOI: 10.15252/embj.201796553] [Citation(s) in RCA: 119] [Impact Index Per Article: 19.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Revised: 03/07/2018] [Accepted: 03/08/2018] [Indexed: 01/04/2023] Open
Abstract
Opa1 participates in inner mitochondrial membrane fusion and cristae morphogenesis. Here, we show that muscle-specific Opa1 ablation causes reduced muscle fiber size, dysfunctional mitochondria, enhanced Fgf21, and muscle inflammation characterized by NF-κB activation, and enhanced expression of pro-inflammatory genes. Chronic sodium salicylate treatment ameliorated muscle alterations and reduced the muscle expression of Fgf21. Muscle inflammation was an early event during the progression of the disease and occurred before macrophage infiltration, indicating that it is a primary response to Opa1 deficiency. Moreover, Opa1 repression in muscle cells also resulted in NF-κB activation and inflammation in the absence of necrosis and/or apoptosis, thereby revealing that the activation is a cell-autonomous process and independent of cell death. The effects of Opa1 deficiency on the expression NF-κB target genes and inflammation were absent upon mitochondrial DNA depletion. Under Opa1 deficiency, blockage or repression of TLR9 prevented NF-κB activation and inflammation. Taken together, our results reveal that Opa1 deficiency in muscle causes initial mitochondrial alterations that lead to TLR9 activation, and inflammation, which contributes to enhanced Fgf21 expression and to growth impairment.
Collapse
Affiliation(s)
- Aida Rodríguez-Nuevo
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.,Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Angels Díaz-Ramos
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.,Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Eduard Noguera
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.,Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Francisco Díaz-Sáez
- Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain
| | - Xavier Duran
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.,Hospital Universitari de Tarragona Joan XXIII-IISPV, Facultat de Medicina, Universitat Rovira i Virgili, Tarragona, Spain
| | - Juan Pablo Muñoz
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.,Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Montserrat Romero
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.,Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Natàlia Plana
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.,Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - David Sebastián
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.,Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | | | | | - Francesc Ribas
- Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.,CIBER Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Barcelona, Spain
| | - Jordi Seco
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.,Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Evarist Planet
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain
| | - Susan R Doctrow
- Department of Medicine, Boston University School of Medicine, Boston, MA, USA
| | - Javier González
- Experimental Toxicology and Ecotoxicology Unit (CERETOX), Barcelona Science Park, Barcelona, Spain
| | - Miquel Borràs
- Experimental Toxicology and Ecotoxicology Unit (CERETOX), Barcelona Science Park, Barcelona, Spain
| | - Marc Liesa
- Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA
| | - Manuel Palacín
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.,Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.,CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain
| | - Joan Vendrell
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.,Hospital Universitari de Tarragona Joan XXIII-IISPV, Facultat de Medicina, Universitat Rovira i Virgili, Tarragona, Spain
| | - Francesc Villarroya
- Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.,CIBER Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Barcelona, Spain
| | - Marco Sandri
- Venetian Institute of Molecular Medicine, Padova, Italy
| | - Orian Shirihai
- Department of Medicine, Boston University School of Medicine, Boston, MA, USA.,Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA
| | - Antonio Zorzano
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain .,Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
4
|
Hernández-Alvarez MI, Díaz-Ramos A, Berdasco M, Cobb J, Planet E, Cooper D, Pazderska A, Wanic K, O'Hanlon D, Gomez A, de la Ballina LR, Esteller M, Palacin M, O'Gorman DJ, Nolan JJ, Zorzano A. Early-onset and classical forms of type 2 diabetes show impaired expression of genes involved in muscle branched-chain amino acids metabolism. Sci Rep 2017; 7:13850. [PMID: 29062026 PMCID: PMC5653857 DOI: 10.1038/s41598-017-14120-6] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2017] [Accepted: 10/03/2017] [Indexed: 02/07/2023] Open
Abstract
The molecular mechanisms responsible for the pathophysiological traits of type 2 diabetes are incompletely understood. Here we have performed transcriptomic analysis in skeletal muscle, and plasma metabolomics from subjects with classical and early-onset forms of type 2 diabetes (T2D). Focused studies were also performed in tissues from ob/ob and db/db mice. We document that T2D, both early and late onset, are characterized by reduced muscle expression of genes involved in branched-chain amino acids (BCAA) metabolism. Weighted Co-expression Networks Analysis provided support to idea that the BCAA genes are relevant in the pathophysiology of type 2 diabetes, and that mitochondrial BCAA management is impaired in skeletal muscle from T2D patients. In diabetic mice model we detected alterations in skeletal muscle proteins involved in BCAA metabolism but not in obese mice. Metabolomic analysis revealed increased levels of branched-chain keto acids (BCKA), and BCAA in plasma of T2D patients, which may result from the disruption of muscle BCAA management. Our data support the view that inhibition of genes involved in BCAA handling in skeletal muscle takes place as part of the pathophysiology of type 2 diabetes, and this occurs both in early-onset and in classical type 2 diabetes.
Collapse
Affiliation(s)
- María Isabel Hernández-Alvarez
- Institute for Research in Biomedicine (IRB Barcelona). The Barcelona Institute of Science and Technology, Barcelona, Spain.,Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, 08028, Barcelona, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Angels Díaz-Ramos
- Institute for Research in Biomedicine (IRB Barcelona). The Barcelona Institute of Science and Technology, Barcelona, Spain.,Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, 08028, Barcelona, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - María Berdasco
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
| | | | - Evarist Planet
- Institute for Research in Biomedicine (IRB Barcelona). The Barcelona Institute of Science and Technology, Barcelona, Spain
| | - Diane Cooper
- National Institute for Cellular Biotechnology, 3U Diabetes Partnership & School of Health and Human Performance, Dublin City University, Dublin, Ireland
| | - Agnieszka Pazderska
- Metabolic Research Unit, St James's Hospital and Trinity College Dublin, Dublin, Ireland
| | - Krzystof Wanic
- Metabolic Research Unit, St James's Hospital and Trinity College Dublin, Dublin, Ireland
| | - Declan O'Hanlon
- Metabolic Research Unit, St James's Hospital and Trinity College Dublin, Dublin, Ireland
| | - Antonio Gomez
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
| | - Laura R de la Ballina
- Institute for Research in Biomedicine (IRB Barcelona). The Barcelona Institute of Science and Technology, Barcelona, Spain.,Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, 08028, Barcelona, Spain
| | - Manel Esteller
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
| | - Manuel Palacin
- Institute for Research in Biomedicine (IRB Barcelona). The Barcelona Institute of Science and Technology, Barcelona, Spain.,Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, 08028, Barcelona, Spain.,CIBERER, Instituto de Salud Carlos III, Madrid, Spain
| | - Donal J O'Gorman
- National Institute for Cellular Biotechnology, 3U Diabetes Partnership & School of Health and Human Performance, Dublin City University, Dublin, Ireland
| | | | - Antonio Zorzano
- Institute for Research in Biomedicine (IRB Barcelona). The Barcelona Institute of Science and Technology, Barcelona, Spain. .,Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, 08028, Barcelona, Spain. .,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.
| |
Collapse
|
5
|
Pablo Muñoz J, Ivanova S, Sánchez-Wandelmer J, Martínez-Cristóbal P, Noguera E, Sancho A, Díaz-Ramos A, Isabel Hernández-Alvarez M, Sebastián D, Mauvezin C, Palacín M, Zorzano A. Mfn2 modulates the UPR and mitochondrial function via repression of PERK. EMBO J 2014. [DOI: 10.1002/embj.201470050] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Affiliation(s)
- Juan Pablo Muñoz
- Institute for Research in Biomedicine (IRB Barcelona); Barcelona Spain
- Departament de Bioquímica i Biologia Molecular; Facultat de Biologia; Universitat de Barcelona; Barcelona Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM); Instituto de Salud Carlos III; Barcelona Spain
| | - Saška Ivanova
- Institute for Research in Biomedicine (IRB Barcelona); Barcelona Spain
- Departament de Bioquímica i Biologia Molecular; Facultat de Biologia; Universitat de Barcelona; Barcelona Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM); Instituto de Salud Carlos III; Barcelona Spain
| | - Jana Sánchez-Wandelmer
- Institute for Research in Biomedicine (IRB Barcelona); Barcelona Spain
- Departament de Bioquímica i Biologia Molecular; Facultat de Biologia; Universitat de Barcelona; Barcelona Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM); Instituto de Salud Carlos III; Barcelona Spain
| | - Paula Martínez-Cristóbal
- Institute for Research in Biomedicine (IRB Barcelona); Barcelona Spain
- Departament de Bioquímica i Biologia Molecular; Facultat de Biologia; Universitat de Barcelona; Barcelona Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM); Instituto de Salud Carlos III; Barcelona Spain
| | - Eduard Noguera
- Institute for Research in Biomedicine (IRB Barcelona); Barcelona Spain
- Departament de Bioquímica i Biologia Molecular; Facultat de Biologia; Universitat de Barcelona; Barcelona Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM); Instituto de Salud Carlos III; Barcelona Spain
| | - Ana Sancho
- Institute for Research in Biomedicine (IRB Barcelona); Barcelona Spain
- Departament de Bioquímica i Biologia Molecular; Facultat de Biologia; Universitat de Barcelona; Barcelona Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM); Instituto de Salud Carlos III; Barcelona Spain
| | - Angels Díaz-Ramos
- Institute for Research in Biomedicine (IRB Barcelona); Barcelona Spain
- Departament de Bioquímica i Biologia Molecular; Facultat de Biologia; Universitat de Barcelona; Barcelona Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM); Instituto de Salud Carlos III; Barcelona Spain
| | - María Isabel Hernández-Alvarez
- Institute for Research in Biomedicine (IRB Barcelona); Barcelona Spain
- Departament de Bioquímica i Biologia Molecular; Facultat de Biologia; Universitat de Barcelona; Barcelona Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM); Instituto de Salud Carlos III; Barcelona Spain
| | - David Sebastián
- Institute for Research in Biomedicine (IRB Barcelona); Barcelona Spain
- Departament de Bioquímica i Biologia Molecular; Facultat de Biologia; Universitat de Barcelona; Barcelona Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM); Instituto de Salud Carlos III; Barcelona Spain
| | - Caroline Mauvezin
- Institute for Research in Biomedicine (IRB Barcelona); Barcelona Spain
- Departament de Bioquímica i Biologia Molecular; Facultat de Biologia; Universitat de Barcelona; Barcelona Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM); Instituto de Salud Carlos III; Barcelona Spain
| | - Manuel Palacín
- Institute for Research in Biomedicine (IRB Barcelona); Barcelona Spain
- Departament de Bioquímica i Biologia Molecular; Facultat de Biologia; Universitat de Barcelona; Barcelona Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM); Instituto de Salud Carlos III; Barcelona Spain
| | - Antonio Zorzano
- Institute for Research in Biomedicine (IRB Barcelona); Barcelona Spain
- Departament de Bioquímica i Biologia Molecular; Facultat de Biologia; Universitat de Barcelona; Barcelona Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM); Instituto de Salud Carlos III; Barcelona Spain
| |
Collapse
|
6
|
Suelves M, Vidal B, Serrano AL, Tjwa M, Roma J, López-Alemany R, Luttun A, de Lagrán MM, Díaz-Ramos A, Díaz MA, Jardí M, Roig M, Dierssen M, Dewerchin M, Carmeliet P, Muñoz-Cánoves P. uPA deficiency exacerbates muscular dystrophy in MDX mice. ACTA ACUST UNITED AC 2007; 178:1039-51. [PMID: 17785520 PMCID: PMC2064626 DOI: 10.1083/jcb.200705127] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Duchenne muscular dystrophy (DMD) is a fatal and incurable muscle degenerative disorder. We identify a function of the protease urokinase plasminogen activator (uPA) in mdx mice, a mouse model of DMD. The expression of uPA is induced in mdx dystrophic muscle, and the genetic loss of uPA in mdx mice exacerbated muscle dystrophy and reduced muscular function. Bone marrow (BM) transplantation experiments revealed a critical function for BM-derived uPA in mdx muscle repair via three mechanisms: (1) by promoting the infiltration of BM-derived inflammatory cells; (2) by preventing the excessive deposition of fibrin; and (3) by promoting myoblast migration. Interestingly, genetic loss of the uPA receptor in mdx mice did not exacerbate muscular dystrophy in mdx mice, suggesting that uPA exerts its effects independently of its receptor. These findings underscore the importance of uPA in muscular dystrophy.
Collapse
Affiliation(s)
- Mònica Suelves
- Program on Differentiation and Cancer, Center for Genomic Regulation, E-08003, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|